Abstract
Abstract The gut microbiota plays an important role in shaping systemic immune response. One novel frontier in cancer research is investigating how the gut microbiota change immune response and influence the efficacy of anticancer immunotherapy drugs; this has been reported in CTLA4 and PD-L1 antibody treatment, both in laboratory and clinical settings. One recent study reported that composition of patient`s gut microbes appears to be a determining factor for immunotherapy, at least in melanoma patients. These findings shed light on the potential use of gut microbial as a biomarker for responders in cancer immunotherapy and even as a novel treatment. Here, we evaluated the gut microbiota profiling upon PD-1 antibody (RMP1-14) treatment in CT-26 colon cancer syngeneic mouse model. Fresh feces were collected at different time points before and after treatment, snap frozen and sent for 16s RNA sequencing for microbiome profiling. Our results identified top 25 abundant taxa in genus level in CT-26 feces. Significant abundance changes were observed in several genera after PD-1 antibody treatment, especially in Akkermansia. These findings indicate that immunotherapy like PD-1 antibody can induce the profile changes of gut microbiota in CT-26 model. Furthermore, we also investigated the correlation of gut microbiome with immune- microenvironment and the efficacy upon IO therapy, as well as the possibility to utilize microbiota profiling as a quality control step that may help to explain the variability observed in many syngeneic studies. Citation Format: Jian Ding, Binchen Mao, Qian Shi. PD-1 antibody treatment induces gut microbiota changes in CT-26 colon cancer syngeneic model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2696. doi:10.1158/1538-7445.AM2017-2696
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
